GlassScriptPhysician profile
Scott A Kono
NPI 1184671067
$438.84
in general payments reported to CMS, 2019-2025
13 companies · $20.32 in 2025
The $20.32 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2023: $194 · 2024: $53.34 · 2025: $20.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.06 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $155.41 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $124.59 | 2021 | |
| Novocure INC. | $29.45 | 2024 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $25.00 | 2023 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.89 | 2024 | |
| Genentech USA, INC. | $22.26 | 2021 | |
| Adaptive Biotechnologies Corporation | $20.32 | 2025 | Clonoseq |
| Celgene Corporation | $13.99 | 2023 | Reblozyl |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.